Introduction
Hepatocellular carcinoma (HCC), one of the malignant cancers which mortality ranks as the fifth in the world, continues to have a great extent of drug resistance and lack of effective treatment [1] . In the last several decades, many patients have succumbed to liver cancer despite extraordinary advances in the technologies related to diagnosis and therapeutic modalities [2] . The efficacy of traditional radiotherapy and chemotherapy methods for treating liver cancer has reached a plateau in recent decades. Therefore, there is an urgent need to develop new techniques in cancer therapy, which has become a prominent area in clinical research. Recently, immunotherapy was shown to improve therapeutic effects as an adjuvant therapy for cancer patients [3] . Immunotherapy can reduce the treatment side effects, increase the therapeutic effect and improve quality of life [4] . Thus, studies that address how to improve the immunotherapeutic effects in liver cancer patients has becomes more important and deserves further consideration.
The tumor microenvironment has been identified and comprises tumor cells, immune cells such as T cells, T regulatory cells (Tregs), dendritic cells, macrophages, cancer-associated fibroblasts or stromal cells, leading to cross activation or suppression of each cell type [5] . Each of these cellular components contributes to the treatment response and patient prognosis. In the HCC microenvironment, effector T cells, Tregs, and macrophages include the majority of immune cell components [6] . Researches have shown that there are different levels of immunosuppression in these immune cells that is related to the cross talk between tumor and immune cells. Whether there is a method that not only improves the function of immune cells in the microenvironment, but also can suppress tumor cells proliferation and relieve the immunosuppression in immune cells is unknown. Inhibiting the cross-talk between tumor cells and immune cells may be an ideal treatment strategy for liver cancer.
Melatonin (N-acetyl-5-methoxytryptamine) is an indolamine that is synthesized and secreted primarily by the pineal gland, and has important functions, such as activating antioxidant enzymes, enhancing anti-aging properties [7] [8] [9] , and possessing anti-tumor activities [8, [10] [11] [12] [13] [14] . A large amount of evidence suggests that melatonin plays an important role in immunoregulation and anti-inflammatory responses [15] . Melatonin can inhibit the production of pro-inflammatory cytokines help to reduce inflammation, which is essential in promoting tumor invasion in the tumor microenvironment [16] . Our previous studies found melatonin can inhibit liver cancer cell proliferation, invasion and metastasis and has a synergistic effect with traditional chemotherapy drugs [17] [18] [19] . However, whether melatonin can block the cross-talk between tumor cells and immune cells in microenvironment and the mechanism involved in this process are unknown.
Exosomes, small membrane vehicles sized in 30-100 nm, contain a wide range of functional proteins, mRNAs, and miRNAs [20] . Recently, we have found exosomes play an important role in mediating cell-to-cell communication [21] . Exosomes secreted by tumor cells can transfer metastatic potential to the recipient cells by changing the immune status of the microenvironment to achieve immune escape of tumor cells [22] . Thus, exosomes have been identified as potent communicators between tumor cells and their microenvironment, thus contributing to an immunosuppressive status. If our results indicate that melatonin can exert anti-tumor function, as well as attenuate the immunosuppressive status in the microenvironment at the same time, these data will certainly deepen our understanding of the anti-tumor function of melatonin. This data may provide a more important theoretical basis for increasing melatonin in the treatment of liver cancer.
The main purpose of the current study was to examine the effect of exosomes derived from melatonin treated hepatocellularcarcinoma cells on macrophages function. We report here that Exo-MT can significantly decrease the expression of PD-L1 and inhibit cytokine secretion on macrophages while Exo-con had the opposite effect. Furthermore, we found Exo-con and Exo-MT regulate PD-L1 expression and cytokine secretion in macrophages through the STAT3 signaling pathway.
Materials and Methods

Cell Culture
The human HCC cell lines HepG2 and Bel-7402 (Cell Bank of the Chinese Academy of Sciences, Shanghai, China) were cultured in high glucose Dulbecco's Modified Eagle's Medium (DMEM, Wisent, Canada) which was added with fetal bovine serum (10%), penicillin (100U/mL) and streptomycin (100mg/mL). Human monocytic THP-1 cells and the murine RAW264.7 macrophages cell line (Cell Bank of the Chinese Academy of Sciences, Shanghai, China) were cultured in Roswell Park Memorial Institute (RPMI 1640, Gibco, USA) culture medium containing 10% fetal bovine serum. THP-1 monocytes were differentiated into macrophages with 100 ng phorbol 12-myristate 13-acetate (PMA, Sigma, P8139) for 48 h.
All cells were cultured at 37°C and with a humidified atmosphere of 5% CO2.
Exosome Isolation and Characterization
Exosomes were isolated from the cell supernatant of untreated cultured HCC cells (Exo-con) or HCC cells treated with melatonin (0.1 mM) (Exo-MT) using ExoQuick Precipitation Solution [23] . ExoQuick-TC TM exosome isolation kits and CD63 antibody were purchased from SBI (System Bioscience, USA). According to the instructions, we firstly collected the cell supernatants, and centrifuged (3000 g, 15 min) to remove cell debris. Then 10 ml of cell supernatant was mixed with 2 ml ExoQuick precipitation solution and incubated overnight at 4°C. Next, the mixture was centrifuged (1500 g, 30 min); the supernatant was discarded, and we centrifuged the sediment again (1500 g, 5 min) to remove excess fluid. Finally we resuspended the sediment with 160 μl PBS and subpackaged before being stored at -80°C. BCA protein assay kit (Beyotime Institute of Biotechnology, China) was used to quantify and standardize the protein concentrations in exosomes. The exosomes are designated as Exo-Con and Exo-MT for simplicity.
Transmission Electron Microscopy (TEM)
TEM was performed to reveal the exosome morphology as previously reported [24] . Briefly, the exosomes were prepared and diluted in PBS (100 μl), and then placed a 20 μl suspension liquid onto formvar carbon-coated copper grids for 1 minute at room temperature. The filter paper was used to removed excess suspension liquid. Next, the 2% phosphotungstic acid (PTA) was used to stain exosomes for 5 minutes at room temperature. Grids were then fixed with 2% glutaraldehyde for 5 minutes, followed by washing with PBS three times. Images were captured under 80 kV with a transmission electron microscope (JEM-1230; Jeol Ltd., Tokyo, Japan).
Immunofluorescence Assay
Immunofluorescence assay was performed to verify that the exosomes could be incorporated by macrophages. Exosomes (100 µl) were dissolved naturally after being removing from -80°C, and labeled with PKH67 (Sigma, Saint Louis, USA) following the manufacturer's procedure. The PKH67-labeled exosomes were co-cultured with macrophages for 12 h. Then the cells were fixed by 4% formaldehyde, and permeabilized with 0.1% Triton. After staining with DAPI, the cells were observed under a confocal microscopy (Leica, German).
Flow Cytometry
THP-1 macrophages were detached from the 12-well plates treated with either Exo-con or Exo-MT. After washing with cold PBS twice, the cells were collected and stained with PE-conjugated anti-human CD274 antibodies (BD Pharmingen). RAW264.7 cells and peritoneal macrophages were stained with FITC-conjugated anti-mouse F4/80 (clone BM8, Biolegend) and APC-conjugated anti-mouse CD274 antibodies (clone 10F.9G2, Biolegend) according to a standard flow cytometry staining protocol. The cells were analyzed by flow cytometry (BD Biosciences) according to the manufacturer's procedure. Flow cytometry data were analyzed using FlowJo (Tree Star) software.
A mouse cytokine bead array (CBA) kit was used to measure IL-10, IL-6, IFN-γ, monocyte chemoattractant protein-1 (MCP-1/CCL2), and TNF-α secretion in the supernatant of RAW264.7 and peritoneal macrophages. A human cytokine bead array (CBA) Kit was used to measure IL-6, IL-8, IL-10, IL-1β, and TNF-α in the supernatant of THP-1 macrophages. The data were acquired using a BD FACS Canto II (BD Biosciences, San Diego, CA) and analyzed using FCAP Array Soft Flow USA (BD Biosciences).
Immunocytochemistry Experiment
The immunocytochemistry experiment was performed using THP-1 derived macrophages co-cultured with either Exo-con or Exo-MT. Briefly, 4% paraformaldehyde was used to fix the cells, 0.1% Triton X-100 was used to permeabilize, and the cells were blocked with 10% normal goat serum for 30 min. The cells were then incubated with a monoclonal antibody E1L3N (Cell Signaling Technology, Cambridge, UK) at 4˚C overnight. Next, the cells were incubated with a HRP conjugated anti-rabbit IgG at 37˚C for 1 h and then stained with DAB Detection Kit according to the manufacturer's instructions. Cells were counterstained with hematoxylin and sealed. Finally, the observed images were captured using an Olympus microscope (Olympus Corporation, Tokyo, Japan).
Animal Experiments
Six-week-old female BALB/c nude mice were purchased from Vital River Laboratory Animal Technology Company (Beijing, China). The animals were housed in a special animal facility where the temperature and humidity was controlled and maintained on a 12-h light/dark cycle. All of the animal experiment procedures were approved by Anhui Medical University Animal Care Committee, and performed in accordance with the guidelines from the National Institutes of Health for the care and use of Laboratory Animals. Nine mice were randomly divided into three groups; PBS group, Exo-con group, and Exo-MT group. They were injected with PBS (100 µl), Exo-con (100 µl), and Exo-MT (100 µl), respectively, from tail veins every other day 10 times. At the end of the experimental period, all mice were sacrificed, and peritoneal macrophages were extracted from the peritoneal irrigation fluid of the mice.
Western Blot Analysis
Western blot analysis was performed as previously described [25] . The STAT3 and p-STAT3, Calnexin antibodies (Cell Signaling Technology, USA) were used as primary antibodies for western blot analysis. S3I-201, an inhibitor of STAT3, was purchased from the Selleck Company, USA. And β-actin antibody was purchased from Zhongshan Biotechnology, Beijing, China. Briefly, the cells and exosomal lysates were centrifuged (12,000 g, 10 minutes) at 4°C, and the supernatants were then collected. Each sample protein was loaded on a 10% gel and separated by SDS-PAGE and subsequently transferred onto a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). Proteins were detected by incubation with a specific antibody at 4°C overnight. The enhanced chemiluminescence reagent (Thermo Fisher, USA) was used to visualize the immunoreactive bands and signals were obtained from an Image Quant™ LAS-4000 Mini Imager (Fuji, Japan). The protein density of each band was determined using Scion Image Software (version 4.0.3.2.) for semi-quantitative analysis.
Statistical Analysis
We used SPSS 16.0 software (SPSS Inc., Chicago, USA) to analyze data. Two-tailed Student's t-test was used to evaluate the difference between the two groups, and three or more comparisons were compared by one-way ANOVA. We independently carried out all the experiments at least three times, and the results are presented as mean ± standard deviation (SD). A value of p < 0.05 was considered statistically significant.
Results
Identification of exosomes with transmission electron microscope and western blot
To study the effects of melatonin on the function of exosomes delivered from tumor cells, we first took measures to verify the isolated pellets we obtained from the supernatant by ExoQuick extracting solution were true exosomes. Each isolated pellet was captured under a transmission electron microscope (TEM) and analyzed by western blotting. Representative TEM images of exosomes obtained from the supernatant of HepG2 cells under different conditions (untreated control, treated with 0.1 mM melatonin) are shown in Fig 1A and Fig 1B, respectively. Homogeneous populations of small cup-shaped circular vesicles (30-100 nm in diameter) were observed. Cellular markers of exosomes were abundant, such as Alix, TSG101, CD63, CD81, CD9, and Hsc70. Among them, CD63 is an evolutionarily conserved protein in exosomes and a widely used biomarker for testing exosomes. Calnexin, is a integral protein of the endoplasmic reticulum (ER) that exists in the cell, which should not appear in exosomes. Thus, we used western blot to further confirm that the isolated pellets were exosomes by detecting CD63 and not Calnexin in all the samples derived from HepG2 cells (Fig. 1C) . These results support the conclusion that the isolated pellets retrieved were true exosomes. Furthermore, we used the BCA protein assay kit to quantify the protein concentration in the Exo-con (60.04 ±1.45 µg/ml) and Exo-MT (57.32 ±4.14 µg/ml). This result suggests that melatonin has no effect on the amount of exosomes secreted by tumor cells. 
Exosomes can be taken up by macrophages
To determine the effects of exosomes on the function of macrophages, we examined whether exosomes could enter macrophages. An immunofluorescence assay was performed by using exosomes labeled with PKH67, a green fluorescence dye. As shown in Fig. 2 , green fluorescence was clearly observed in macrophages around nuclei using the confocal microscope, which supported the conclusion that the extracellular exosomes could be taken up by macrophages. 
Exosomes delivered from hepatocellularcarcinoma cells with or without melatonin treatment regulated the expression of PD-L1 and cytokine secretion in macrophages
To further test the impact of exosomes on the immune function of macrophages, exosomes delivered from liver cancer cells (Exo-con) and exosomes delivered from melatonin treated liver cancer cells (Exo-MT) were incubated with THP-1 macrophages. Exo-con increased the expression of PD-L1 on the PMA-induced THP-1 differentiated macrophages, approxiamtely four times more than that in the control group as determined by flow cytometry (Fig. 3A) . These results suggest Exo-con may suppress the immune status in tumor microenvironment by up-regulating PD-L1 expression on macrophages. Surprisingly, Exo-MT could significantly reverse this effect, reducing PD-L1 expression on macrophages. This phenomenon was further confirmed by using exosomes derived from another HCC cell line Bel-7402 cells (data not shown) and in mouse RAW264.7 macrophages (Fig. 3B) .
To further confirm these results in vitro, an immunocytochemistry experiment using THP-1 derived macrophages to demonstrate PD-L1 expression was performed. As shown in Fig. 4 the control group had virtually no expression of PD-L1 (no brown color), while the Exo-con group (much more brown color) induced PD-L1 positive expression, which indicated that Exo-con indeed upregulated PD-L1 expression on macrophages. Furthermore, Exo-MT could reverse the upregulation of PD-L1 expression presenting less brown color compared with the Exo-con group regardless of magnification.
To further understand the impact of exosomes, obtained from tumor cells under different treatments, on the function of macrophages, we quantified the amount of cytokines secreted by THP-1 differentiated macrophages that were treated with either Exo-con or Exo-MT by the cytokine bead array (CBA) inflammatory cytokines kit. As shown in Fig. 5 , IL-6, IL-1β, IL-10, and TNF-α were significantly up-regulated in the Exo-con group compared to the control group, while these cytokines were significantly decreased in the Exo-MT group compared to Exo-con group. These finding suggest that exosomes secreted by tumor cells under different conditions can influence the cytokines secretion profile of macrophages.
To further confirm the results we obtained in vitro, we performed experiments in vivo by injecting PBS (100 µl), Exo-con (50 µg/ml, 100 µl), or Exo-MT (50 µg/ml, 100 µl) through the tail vein into mice once every other day 10 times. Peritoneal macrophages were then isolated, and exosomes injected into mice from the tail vein could also enter into peritoneal macrophages (Fig. 6A) . Our results indicated that the Exo-con group upregulated PD-L1 expression on macrophages, while the Exo-MT group lower the expression of PD-L1 (Fig. 6B) . Moreover, cytokines such as IL-6, TNF-α, IFN-γ, and IL-10, were all up-regulated in the Exo-con group, while Exo-MT group induced less expression of these cytokines compared with Exo-con group. Furthermore, Exo-con did not upregulate MCP-1 levels, while Exo-MT downregulated the MCP-1 level. (Fig. 6C) Figure 3 . PD-L1 expression on THP-1 differentiated macrophages and RAW264.7 macrophages regulated by Exo-con and Exo-MT. THP-1 derived macrophages (Blank Group) to slightly express PD-L1, but when treated with Exo-con, (A) PD-L1 expression was upregulated almost four times over compared with the Blank Group while Exo-MT could reverse the upregulation of PD-L1 expression. In RAW264.7 macrophages, we found similar results, (B) Exo-con upregulated PD-L1 expression, while Exo-MT attenuated the effect. We used SPSS 16.0 software (SPSS Inc., Chicago, IL, USA) for statistical analysis of the flow cytometry analysis results in THP-1 derived macrophages (C) and RAW264.7 macrophages (D) . Data are presented as mean ± SD (error bar) of at least three independent experiments. * and ** represent P < 0.05 and P < 0.01, respectively. Red dotted line represents isotype control; blue dotted line, respectively, represents Exo-con and Exo-MT (A).
Exo-con and Exo-MT regulate PD-L1 and cytokine expression through the STAT3 signal pathway
To further understand the detailed mechanism underlying the alterations on macrophages with exosomes, we examined the STAT3 pathway, which might be involved in the regulation of PD-L1 expression and cytokine secretion through western blot analysis [26, 27] . As shown in Fig. 7A , the active STAT3 transcription factor, phosphorylated STAT3 (p-STAT3), was upregulated in the Exo-con group, while the active form was significantly downregulated in the Exo-MT group compared to the Exo-con group. To establish this mechanism more clearly, we verified that the STAT3 signal pathway was indeed active during exosome incubation by using the STAT3 inhibitor S3I-201 (100 µM) (Fig. 7C) .
With the addition of the inhibitor PD-L1 expression on macrophages treated by Exo-con was reduced (Fig.  7E) , which provided further support that the STAT3 pathway participates in the regulation of PD-L1 expression by exosomes.
Discussion
Since an immunosuppressive state is one of the most important factors in tumor progression, it has recently received increased attention in clinical tumor therapy [3] , especially in HCC, which lacks efficient therapeutic methods in clinical treatment. In addition, it has been widely reported that tumor cells can cause an immunosuppressive state in the tumor microenvironment via unknown mechanisms [28] . Thus, it is useful to begin to reveal the possible mechanisms that result in an immunosuppression state. In this study, we have observed that tumor cell-delivered exosomes can upregulate PD-L1 expression and the secretion of cytokines, which may contribute to immunosuppressive status in macrophages. The most important finding of the present study, however, is that exosomes derived from melatonin treated hepatocellularcarcinoma cells could attenuate the immunosuppressive status on macrophages both in vitro and in vivo (Fig 8) .
Melatonin has been widely reported to regulate the immune system, both within the innate immune response and the adaptive immune response [29] . Melatonin can have an impact on many immune cells to achieve the function of immune regulation. In an innate immune response, melatonin can modulate the main cellular components, such as macrophages, NK cells and monocytes, by increasing cellularity or promoting cell activity [30] . It has been reported that melatonin has anti-inflammatory effects in LPS-stimulated RAW264.7 macrophages [31] . However, no information exists on whether melatonin can alter tumor cells to attenuate an immunosuppressive state. The present results indicate that exosomes, derived from hepatocellularcarcinoma cells treated with melatonin 0.1 mM, significantly decreased PD-L1 and cytokine secretion from macrophages. When hepatocellularcarcinoma cells were treated with melatonin, melatonin not only functioned as a cytotoxic drug but also modulates the exosomic properties secreted by tumor cells to attenuate the immunosuppressive state of macrophages. Hence, we conclude that melatonin indeed has effects on immune regulation and can even relieve the immunosuppressive state caused by tumor cells through exosomes. Our results suggest that melatonin may be a potential and efficient drug that has the potential to be used as a future liver cancer immunotherapy, which will certainly widen the application of melatonin in clinic treatments. PD-L1 (B7-H1, CD274) is a ligand for PD-1, which decreases anti-tumor immunity by inducing T cell apoptosis, energy exhaustion, or IL-10 production when combined with PD-1 [32] . The PD-1 and PD-L1 pathway blockade has become an advanced and active research area that elicits durable anti-tumor responses and long time remissions in a certain numbers of patients with different types of cancers [33] . Thus, how to further improve and widen the clinical effect of anti-PD therapy is a crucial topic in the field of cancer immunology and immunotherapy. PD-L1 usually exists in tumor cells, but high levels of PD-L1 protein expression has been observed in APCs (dendritic cells, macrophages), and fibroblasts [32] . It has been reported that PDL1 + macrophages were enriched predominantly in the peritumoral stroma of HCC [34] . Moreoever, the expression of PD-L1 on macrophages have an immunosuppressive function, such as suppressing tumor-specific T cell immunity, and contribute to the growth of human tumors [35] . Viral infection can increase the PDL1 expression on macrophages, [36] while we found both Exo-con and Exo-MT could change the PD-L1 expression on macrophages. Thus, we tentatively postulate that melatonin may decrease the PD-L1 expression on macrophages through regulating the function of tumor exosomes, which would be the most important currently known mechanism of melatonin in anti-tumor function.
Cytokine secretion is an important mechanism by which macrophages exert immune regulatory functions. Cytokines secreted by macrophages play a crucial role both in the inflammation progress and the immune state, which may be a potential target or indicator reflecting the microenvironment state [37] . Tumor-derived exosomes can stimulate secretion of pro-inflammatory cytokines in recipient cells, including IL-6, TNF, TGF-β and can promote suppression of T cell function and their proliferation [38] . Similarly, we found both Exo-con and Exo-MT could change cytokines secretion in macrophages. Interleukin-6 (IL-6), one of the major cytokines in the tumor microenvironment, is an important factor that is highly expressed in most cancers as reported. It can regulate almost all hallmarks of cancer and has multiple signaling pathways, including apoptosis, survival, proliferation, invasiveness and metastasis, to promote tumorigenesis [39] . Our studies indicated that IL-6 secreted by macrophages was highly up-regulated in the Exo-con group compared to that in the control and Exo-MT group, which is consistent with the change in PD-L1 expression. Interleukin-10 (IL-10), a negative factor in regulating the immune system was found to be up-regulated in the Exo-con group, which would play a crucial role in suppressing the immune system for the tumor microenvironment [40] . However, Exo-MT significantly decreased IL-10 level, which may help to restore the immune function in the tumor microenvironment. IL-1b, one of the inflammatory cytokines, is associated with the pathogenesis and progression in many diseases [41] . Induction of IL-1β could promote breast cancer cells invasion and metastasis development [42] . Our results indicated IL-1β levels were significantly increased in Exo-con group, which would be beneficial for tumor progression, while Exo-MT could reverse IL-1β up-regulation. Another important cytokine we studied is tumor necrosis factor-α (TNFα), a key multifunctional cytokine with pleiotropic actions that regulate immune responses [43] . Furthermore, TNFα could regulate the epithelial mesenchymal transition (EMT) process which is associated with tumor progression, metastasis and drug resistance [44] . In present study, TNFα levels were significantly up-regulated in the Exo-con group while decreased in Exo-MT group, which would be highly related to the immune status in the tumor microenvironment. Thus, the results above indicated that the exosomes derived from melatonin treated hepatocellularcarcinoma cells could regulate the immune status through cytokines secretion in macrophages. Western blot analysis of STAT3 signal pathway key-protein level. (A) p-STAT3 protein level from Exo-con treated THP-1 differentiated macrophages were obviously increased compared with the Blank Group, while the Exo-MT treated group showed reduced p-STAT3 expression. Specific STAT3-inhibitor S3I-201 indeed inhibited the upregulation of p-STAT3 expression in the Exo-con Group (C). When macrophages were treated with Exo-con combined with S3I-201, PD-L1 expression decreased (E). Data are presented as mean ± SD (error bar) of at least three independent experiments. *and ** represent P < 0.05 and P < 0.01, respectively. STAT3, key active regulators of immunity and inflammation, has been shown to regulate PD-L1 and cytokine secretion [45] . Thus, we studied the changes of STAT3 signal pathway in macrophages separately co-cultured with Exo-con and Exo-MT, and found the levels of STAT3 activation indeed changed which were in consistent with the PD-L1 expression as well as cytokine secretion. We confirmed this by using STAT3 inhibitory S3I-201, p-STAT3 was significantly reduced while PD-L1 expression decreased.
In conclusion, we have found that liver cancer cell-delivered exosomes can up-regulate PD-L1 expression and cytokine secretion in macrophages. However, the exosomes secreted by liver cancer cells after treatment by melatonin did not cause the same effects, which means that melatonin could change the function of tumor exosomes to attenuate immunosuppression in macrophages. The possible mechanism was associated with regulating the STAT3 signal pathway. Our study and previous studies provide evidence to support melatonin is functioned not only as a cytotoxic drug but also can change the function of tumor exosomes to attenuate immunosuppressive status in tumor microenvironment. Thus, the use of melatonin to treat primary liver cancers may be of clinical value in the future. microRNAs; HCC: hepatoma carcinoma cell; PD-L1: programmed death ligand 1; MT: melatonin; Exo-con: hepatocellularcarcinomaderived exosomes; Exo-MT: exosomes derived from hepatocellularcarcinoma cells treated with 0.1 mM melatonin; mRNA: messenger RNA; SD: standard error; TEM: transmission electron microscopy; FCM: flow cytometry; CBA: cytokine bead array; PTA: phosphotungstic acid.
